GlassScriptPhysician profile
Stacey E Warburton
NPI 1194282483
$4,121.38
in general payments reported to CMS, 2019-2025
14 companies · $869 in 2025
The $869 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,174 · 2022: $754 · 2023: $206 · 2024: $1,118 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,899 · Food and Beverage: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,898.74 |
| Food and Beverage | $294.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,898.74 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $677.31 | 2022-2025 | |
| Daiichi Sankyo INC. | $383.22 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $249.93 | 2021 | |
| Puma Biotechnology, INC. | $219.33 | 2021-2022 | |
| Genzyme Corporation | $106.15 | 2021 | |
| Incyte Corporation | $99.95 | 2021 | |
| Eisai INC. | $87.96 | 2021 | |
| Amgen INC. | $87.42 | 2021 | |
| Seagen INC. | $85.35 | 2021 | |
| Coherus Oncology, INC. | $75.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.76 | 2021 | |
| Dova Pharmaceuticals | $64.62 | 2021 | |
| Gilead Sciences, INC. | $13.64 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Warburton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.